Register

COURSE DESCRIPTION:  

Multiple myeloma is primarily treated by hematologists; however, it is important for primary care providers to understand the presentation and diagnosis of this disease. Multiple myeloma is often seen in people 65 and older though less than one percent of cases are diagnosed in people younger than 35. Often, the initial signs and symptoms of the disease are subtle and require the primary care providers’ keen observation to diagnose and initiate a workup. Despite improved survival for newly diagnosed multiple myeloma, approximately twenty percent of people newly diagnosed have substantially worse outcomes. An update on the diagnosis, prognosis and management of Multiple Myeloma for the internist will be discussed in this lecture. 

TARGET AUDIENCE:

Internal Medicine Physicians, Physician Assistants, Residents,  Advanced Practice Registered Nurses, Pharmacists and all other interested healthcare providers. 

LEARNING OBJECTIVES:

•    Discuss updates on the diagnosis of Multiple Myeloma for the internist.
•    Discuss updates on management of patients with multiple myeloma. 

FACULTY AND DISCLOSURES:

Warren S. Brenner, M.D. 
Co-chief Gastrointestinal Medical Oncology
Internal Medicine
Center for Hematology/Oncology 
Lynn Cancer Institute 
Baptist Health South Florida
Boca Raton, Florida

Warren S. Brenner, M.D. , faculty for this educational activity, indicated that he is a speaker for Takeda Pharmaceutical Company and Bristol Myers Squibb, and has indicated that the presentation or discussion will not include off-label or unapproved product usage. All of the relevant financial relationships listed have been mitigated.

John Rubin, M.D., director for this educational event, owns stock in AstraZeneca and Bristol Myers Squibb. He has indicated that the presentation or discussion will not include off-label or unapproved product usage. All of the relevant financial relationships listed for this individual have been mitigated.  

Kenneth Rosenthal, M.D., FACG, moderator for this educational event, indicated that he is on the Speaker’s Bureau for AbbVie, Inc. All of the relevant financial relationships listed for this individual has been mitigated. 

Non-faculty contributors and others involved in the planning, development and editing/review of the content have no relevant financial relationships to disclose with ineligible companies.*

*Ineligible companies – Companies whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients.
 

Disclosure Policy and Disclaimer

ACCREDITATION STATEMENTS AND CREDITS

Baptist Health South Florida is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Baptist Health South Florida designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.   

This activity has been approved for 1 credit hour, CE Broker Course #20-855339, by the Florida Boards of Medicine, Podiatry, Dentistry, Osteopathic Medicine and Physician Assistants.  

This activity has also been approved for 1 credit for Nurse Practitioners, Nurses, Pharmacists and Pharmacy Techs, Athletic Trainers. Baptist Health South Florida CE Broker Provider #50-182.